Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer

•We evaluated radiation with dual EGFR and PI3K targeting in head and neck cancer.•Dacomitinib, showed an inverse correlation between growth inhibition and EGFR expression.•Gedatolisib was effective in each cell line. Neither drug caused radiosensitization in vitro.•Gedatolisib was relatively ineffective in vivo in combination with dacomitinib and/or radiation.•Dacomitinib was highly effective alone and in combination with radiation and/or gedatolisib.•Immunoblotting studies in vivo mirrored the effects seen with growth delay.